National Heart, Lung and Blood Institute to Consider Exclusive Patent License for Nasopharyngeal Cancer Treatment

Summary

The National Heart, Lung and Blood Institute, part of the National Institutes of Health and the Department of Health and Human Services, is considering granting an exclusive patent license to Molecular Targeting Technologies, Inc., a Delaware-based company with its headquarters in West Chester, Pennsylvania, to use patents related to treating nasopharyngeal cancer.